{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:52:04Z","timestamp":1787316724100,"version":"build-2736575974"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Motif BioSciences, Inc"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jgar.2018.10.018","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T12:19:34Z","timestamp":1540556374000},"page":"236-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["In vitro activity of dihydrofolate reductase inhibitors and other antibiotics against Gram-positive pathogens collected globally between 2004 and 2016"],"prefix":"10.1016","volume":"16","author":[{"given":"Stephanie","family":"Noviello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hawser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8228-7911","authenticated-orcid":false,"given":"David B.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2018.10.018_bib0005","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2217\/fmb-2018-0061","article-title":"Iclaprim, a dihydrofolate reductase inhibitor antibiotic in phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety","volume":"13","author":"Huang","year":"2018","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jgar.2018.10.018_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3948626","article-title":"In vitro activity of iclaprim against methicillin-resistant Staphylococcus aureus nonsusceptible to daptomycin, linezolid, or vancomycin: a pilot study","author":"Huang","year":"2017","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.jgar.2018.10.018_bib0015","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1093\/jac\/dku174","article-title":"Emergence of trimethoprim resistance gene dfrG in Staphylococcus aureus causing human infection and colonization in sub-Saharan Africa and its import to Europe","volume":"69","author":"Nurjadi","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.10.018_bib0020","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.cmi.2015.08.021","article-title":"Predominance of dfrG as determinant of trimethoprim resistance in imported Staphylococcus aureus","volume":"21","author":"Nurjadi","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2018.10.018_bib0025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3399\/bjgp13X665198","article-title":"Trimethoprim prescription and subsequent resistance in childhood urinary infection: multilevel modelling analysis","volume":"63","author":"Duffy","year":"2013","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.jgar.2018.10.018_bib0030","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014seventh edition. CLSI document M07-A7","author":"Clinical and Laboratory Standards Institute","year":"2006"},{"key":"10.1016\/j.jgar.2018.10.018_bib0035","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition. CLSI document M07-A10","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.jgar.2018.10.018_bib0040","series-title":"Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"10.1016\/j.jgar.2018.10.018_bib0045","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. CLSI document M100-S25","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.jgar.2018.10.018_bib0050","series-title":"Performance standards for antimicrobial susceptibility testing. CLSI supplement M100","author":"Clinical and Laboratory Standards Institute","year":"2017"},{"key":"10.1016\/j.jgar.2018.10.018_bib0055","series-title":"42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 27\u201330 September 2002; San Diego, CA","article-title":"AR-100, a novel diaminopyrimidine compound: bactericidal activity and post-antibiotic effect on Gram-positive pathogens","author":"Hawser","year":"2002"},{"key":"10.1016\/j.jgar.2018.10.018_bib0060","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1503\/cmaj.111152","article-title":"Considerations when prescribing trimethoprim\u2013sulfamethoxazole","volume":"183","author":"Ho","year":"2011","journal-title":"CMAJ"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518302078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518302078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T18:48:31Z","timestamp":1553626111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716518302078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":12,"alternative-id":["S2213716518302078"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2018.10.018","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of dihydrofolate reductase inhibitors and other antibiotics against Gram-positive pathogens collected globally between 2004 and 2016","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2018.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}